William Blair analyst Myles Minter has reiterated their bullish stance on NBIX stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Myles Minter has given his Buy rating due to a combination of factors influencing Neurocrine’s performance. The company’s second-quarter earnings report showed that Ingrezza’s revenue was consistent with both the firm’s and market expectations, demonstrating a steady growth pattern. Despite concerns about the narrowing sales guidance for 2025 and potential pricing pressures, the increase in patient volumes suggests a positive outlook for future growth.
Additionally, the launch of Crenessity has exceeded expectations, with significant revenue surpassing estimates and a strong start in the CAH market. The high reimbursement rate for dispensed products indicates robust market acceptance and potential for sustained revenue growth. These factors combined provide a solid foundation for Minter’s optimistic view on Neurocrine’s stock, supporting the Buy rating.
In another report released yesterday, TD Cowen also maintained a Buy rating on the stock with a $170.00 price target.